Stratification of Breast Tumors Based on ER, PR and HER2 Expression and Activity

SRM Assay Development

Goal – To develop a multiplexed assay for the measurement of total expression and regulatory phosphorylation site levels of Estrogen Receptor alpha, Progesterone Receptor beta and HER2 that could be used in classification of Breast tumors.

Outcome – A triple-protein immunoprecipitation

Collaborators Moffitt Cancer Center, Tampa, Florida and Buck Institute for Research on Aging, Novato, California 

View all case studies